Influenza A Virus, H5N1 Subtype
Conditions
Keywords
vaccine, adjuvant, Influenza in Birds, MF59, AS03
Brief summary
The main purpose of this study is to assess the ability of H5 influenza virus vaccines and adjuvants present in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) to generate an immune response to homologous and to antigenically distant heterologous H5 influenza virus strains. The study is designed to evaluate the safety and immunogenicity of vaccination strategies with homologous or antigenically distant heterologous H5 influenza virus vaccines administered with AS03 or MF59 adjuvant.
Interventions
BIOLOGICALVN
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
BIOLOGICALIN
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
BIOLOGICALdk/BANG
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
BIOLOGICALgf/WA
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
BIOLOGICALbhg/QL
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
BIOLOGICALAS03 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
BIOLOGICALMF59 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
Sponsors
Biomedical Advanced Research and Development Authority
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
1. Is a male or nonpregnant female 18 to 49 years of age, inclusive, on Day 1 (first vaccination). 2. Will avoid nonstudy vaccinations until 21 days after the last vaccination. 3. Provides written informed consent prior to the initiation of any study-related procedures. 4. Has a stable health status, as established by physical examination, vital sign measurements, and medical history. 5. Has access to a consistent and reliable means of telephone contact, which may be in the home, workplace, or by personal mobile electronic device. 6. Is able to understand and comply with planned study procedures. 7. Lives a reasonable distance from the site to be able to travel to and from the site for follow-up visits and agrees to go to the site for evaluation in the case of an adverse event. 8. Agrees to stay in contact with the site for the duration of the study, has no current plans to move from the study area, and provides updated contact information as necessary.
Exclusion criteria
1. Has a known allergy to eggs or other components of the vaccine (including gelatin, formaldehyde, octoxinol-9, thimerosal, or chicken protein), or allergy to squalene-based adjuvants or has had severe reactions following previous immunizations with contemporary influenza virus vaccines. 2. A woman who has a positive urine pregnancy test prior to vaccination in this study or a woman who is breastfeeding. 3. A female of childbearing potential (a) who refuses to use an acceptable method of birth control (b) from Day 1 (first vaccination) to end-of-study visit and, if sexually active, who has not used a reliable birth control method for at least 2 months prior to Day 1 (first vaccination). 1. Female of childbearing potential is defined as post-onset menarche and premenopausal female capable of becoming pregnant. This does not include females who meet any of the following conditions: menopausal \>1 year, tubal ligation \>1 year, bilateral salpingo-oophorectomy, or hysterectomy. 2. Adequate contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly and, when applicable, in accordance with the product label, for example: abstinence from penile-vaginal intercourse; oral contraceptives, either combined or progestogen alone; injectable progestogen; implants of etonogestrel or levonorgestrel; estrogenic vaginal ring; percutaneous contraceptive patches; intrauterine device or intrauterine system; male partner sterilization at least 6 months prior to the female Day 1 (first vaccination), and this male is the sole partner for that subject (The information on the male sterility can come from the site personnel's review of the subject's medical records or interview with the subject on her medical history); male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository); male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository). 4. Is immunosuppressed as a result of an underlying illness or treatment, or anticancer chemotherapy or radiation therapy (cytotoxic) within the preceding 36 months prior to Day 1 (first vaccination). 5. Has an active neoplastic disease or a history of any hematologic malignancy. A subject with superficial skin cancer who does not require intervention other than local excision is not excluded. 6. Has long-term use (≥14 consecutive days) of glucocorticoids including oral or parenteral prednisone or equivalent (\>20 mg total dose per day) or high-dose inhaled steroids (\>800 mcg/day of beclomethasone dipropionate or equivalent) within 1 month prior to screening. (Low-dose \[≤800 mcg/day of beclomethasone dipropionate or equivalent\] inhaled and topical steroids are allowed). 7. Has a diagnosis of schizophrenia, bipolar disease, or other major psychiatric diagnosis. 8. Has been hospitalized for psychiatric illness, history of suicide attempt, or confinement for danger to self or others, within the past 10 years. 9. Has a neurological or psychiatric diagnosis, which, although stable, is judged by the investigator to render the potential subject unable or unlikely to comply with the protocol or to provide accurate safety reports. 10. Has received immunoglobulin or other blood product (with the exception of Rho\[D\] immune globulin) within the 3 months prior to Day 1 (first vaccination). 11. Has received any live vaccine within 4 weeks or inactivated vaccines within 2 weeks prior to Day 1 (first vaccination). This includes seasonal influenza vaccines. 12. Has an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses. This includes potentially immune-mediated medical conditions such as Guillain-Barré syndrome, narcolepsy, current or history of autoimmune or chronic inflammatory disease. 13. Has a first-degree relative with narcolepsy. 14. Has an acute illness, including body temperature greater than 100.4°F, at screening, immediately prior to each vaccination or, per subject report, within 3 days prior to each vaccination. Subjects with an acute illness can be rescheduled for a vaccination as long as the vaccination visit is within the visit window. Note that subjects may return for randomization following resolution of the acute illness as long as recruitment remains open and subjects are within 14 days of signing consent. 15. Has a Grade 2 or greater (by US Food and Drug Administration toxicity grade) safety laboratory value at screening. 16. Has received an experimental agent (vaccine, biologic, device, blood product, or medication) within 1 month prior to Day 1 (first vaccination) in this study or plans receipt of an experimental agent during the study period. 17. Is participating or plans to participate in another interventional clinical study (either active or follow-up phase) during the study period. 18. Has received an influenza H5 vaccine in the past or has a history of H5 influenza infection prior to enrollment. 19. Has known human immunodeficiency virus, hepatitis B, or hepatitis C infection. 20. Has a history of alcohol or drug abuse within 5 years prior to Day 1 (first vaccination). 21. Has a body mass index \>35 kg/m2. 22. Has any condition that would, in the opinion of the investigator, place him or her at an unacceptable risk of injury or render him or her unable to meet the requirements of the protocol (including site of injection reactogenicity assessments). 23. Is a first-degree relative of any person working on this study: site or sponsor.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | 8 days post-vaccination | Safety of 2-dose and 3-dose H5 influenza vaccination series as determined by occurrence of mild, moderate, or severe solicited local reactogenicity symptoms. Subjects in A-D and G-J did not receive 3 doses |
| Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | 8 days post-vaccination | Safety of 2-dose and 3-dose H5 influenza vaccination series as determined by occurrence of mild, moderate, or severe solicited systemic reactogenicity symptoms Subjects in A-D and G-J did not receive 3 doses |
| Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | Day 43 | Serum hemagglutination inhibition (HAI) antibody seroprotection rate (SPR) |
| Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | Day 163 | Serum hemagglutination inhibition (HAI) antibody seroprotection rate (SPR) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant Single dose of Vietnam (VN) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/Washington (WA) (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
VN: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
AS03 adjuvant: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose | 60 |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant Single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
IN: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
AS03 adjuvant: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose | 58 |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant Single dose of dk/Bangladesh (BANG) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
dk/BANG: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
AS03 adjuvant: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose | 61 |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant Single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
IN: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
AS03 adjuvant: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose | 60 |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant Two doses of dk/BANG (H5N1) vaccine with AS03 Adjuvant (Dose1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/Qinghai Lake(QL) (H5N1) vaccine with AS03 Adjuvant (Day 142).
dk/BANG: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
bhg/QL: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
AS03 adjuvant: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose | 59 |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant Two doses of gf/WA (H5N3) vaccine with AS03 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with AS03 Adjuvant (Day 142)
gf/WA: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
bhg/QL: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
AS03 adjuvant: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose | 62 |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant Single dose of VN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
VN: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
MF59 adjuvant: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose | 59 |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant Single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
IN: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
MF59 adjuvant: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose | 60 |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant Single dose of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
dk/BANG: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
MF59 adjuvant: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose | 61 |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant Single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
IN: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
MF59 adjuvant: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose | 59 |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant Two doses of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
dk/BANG: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
bhg/QL: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
MF59 adjuvant: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose | 61 |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant Two doses of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
gf/WA: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
bhg/QL: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
MF59 adjuvant: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose | 60 |
| Total | 720 |
Baseline characteristics
| Characteristic | b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized Age of Participants 18-<30 years old | 23 Participants | 26 Participants | 26 Participants | 24 Participants | 21 Participants | 24 Participants | 23 Participants | 18 Participants | 34 Participants | 18 Participants | 22 Participants | 25 Participants | 284 Participants |
| Age, Customized Age of Participants 30-<40 years old | 15 Participants | 23 Participants | 17 Participants | 21 Participants | 17 Participants | 15 Participants | 17 Participants | 22 Participants | 13 Participants | 26 Participants | 14 Participants | 19 Participants | 219 Participants |
| Age, Customized Age of Participants 40-49 years old | 20 Participants | 12 Participants | 17 Participants | 14 Participants | 24 Participants | 20 Participants | 20 Participants | 20 Participants | 14 Participants | 15 Participants | 25 Participants | 16 Participants | 217 Participants |
| Body Mass Index (BMI) (kg/m^2) | 26.750 kg/m^2 STANDARD_DEVIATION 5.3287 | 27.561 kg/m^2 STANDARD_DEVIATION 5.1079 | 26.840 kg/m^2 STANDARD_DEVIATION 4.4868 | 26.458 kg/m^2 STANDARD_DEVIATION 4.4476 | 26.495 kg/m^2 STANDARD_DEVIATION 4.2461 | 26.798 kg/m^2 STANDARD_DEVIATION 4.6794 | 26.637 kg/m^2 STANDARD_DEVIATION 4.4123 | 27.297 kg/m^2 STANDARD_DEVIATION 4.546 | 26.457 kg/m^2 STANDARD_DEVIATION 4.7881 | 26.824 kg/m^2 STANDARD_DEVIATION 3.9945 | 26.867 kg/m^2 STANDARD_DEVIATION 4.03 | 26.268 kg/m^2 STANDARD_DEVIATION 4.762 | 26.771 kg/m^2 STANDARD_DEVIATION 4.5691 |
| Race/Ethnicity, Customized Ethnicity of Participants Hispanic or Latino | 7 Participants | 6 Participants | 5 Participants | 6 Participants | 5 Participants | 7 Participants | 4 Participants | 7 Participants | 5 Participants | 4 Participants | 7 Participants | 5 Participants | 68 Participants |
| Race/Ethnicity, Customized Ethnicity of Participants Not Hispanic or Latino | 51 Participants | 55 Participants | 55 Participants | 53 Participants | 57 Participants | 52 Participants | 56 Participants | 53 Participants | 56 Participants | 55 Participants | 54 Participants | 55 Participants | 652 Participants |
| Race/Ethnicity, Customized Race of Participants American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Race of Participants Asian | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 2 Participants | 2 Participants | 1 Participants | 2 Participants | 2 Participants | 4 Participants | 1 Participants | 1 Participants | 19 Participants |
| Race/Ethnicity, Customized Race of Participants Black or African American | 10 Participants | 14 Participants | 5 Participants | 13 Participants | 11 Participants | 10 Participants | 8 Participants | 6 Participants | 12 Participants | 11 Participants | 14 Participants | 8 Participants | 122 Participants |
| Race/Ethnicity, Customized Race of Participants Multiracial | 5 Participants | 4 Participants | 5 Participants | 2 Participants | 2 Participants | 2 Participants | 0 Participants | 4 Participants | 2 Participants | 3 Participants | 4 Participants | 7 Participants | 40 Participants |
| Race/Ethnicity, Customized Race of Participants Native Hawaiian or Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race of Participants Other | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 3 Participants |
| Race/Ethnicity, Customized Race of Participants White | 42 Participants | 42 Participants | 49 Participants | 42 Participants | 47 Participants | 44 Participants | 51 Participants | 48 Participants | 45 Participants | 41 Participants | 42 Participants | 42 Participants | 535 Participants |
| Sex: Female, Male Female | 32 Participants | 35 Participants | 40 Participants | 38 Participants | 31 Participants | 43 Participants | 37 Participants | 31 Participants | 42 Participants | 28 Participants | 35 Participants | 38 Participants | 430 Participants |
| Sex: Female, Male Male | 26 Participants | 26 Participants | 20 Participants | 21 Participants | 31 Participants | 16 Participants | 23 Participants | 29 Participants | 19 Participants | 31 Participants | 26 Participants | 22 Participants | 290 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 60 | 0 / 58 | 0 / 61 | 0 / 60 | 1 / 59 | 0 / 62 | 0 / 59 | 0 / 60 | 0 / 61 | 0 / 59 | 0 / 61 | 0 / 60 |
| other Total, other adverse events | 46 / 60 | 45 / 58 | 44 / 61 | 43 / 60 | 47 / 59 | 47 / 62 | 40 / 59 | 36 / 60 | 40 / 61 | 41 / 59 | 45 / 61 | 42 / 60 |
| serious Total, serious adverse events | 1 / 60 | 2 / 58 | 1 / 61 | 0 / 60 | 2 / 59 | 0 / 62 | 2 / 59 | 1 / 60 | 0 / 61 | 0 / 59 | 4 / 61 | 1 / 60 |
Outcome results
Primary
Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series
Safety of 2-dose and 3-dose H5 influenza vaccination series as determined by occurrence of mild, moderate, or severe solicited local reactogenicity symptoms. Subjects in A-D and G-J did not receive 3 doses
Time frame: 8 days post-vaccination
Population: If a subject experienced multiple occurrences of the same solicited local AE, only the most severe solicited local AE was counted. If a subject had multiple AEs the number of events analyzed may be greater than the overall number of participants analyzed.~Subjects in A-D and G-J did not receive 3 doses
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Mild | 43 Events |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Mild | 27 Events |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Severe | 0 Events |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Severe | 0 Events |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Moderate | 5 Events |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Moderate | 3 Events |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Moderate | 5 Events |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Mild | 32 Events |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Moderate | 4 Events |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Severe | 0 Events |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Mild | 28 Events |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Severe | 0 Events |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Mild | 35 Events |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Mild | 27 Events |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Severe | 0 Events |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Moderate | 3 Events |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Moderate | 6 Events |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Severe | 1 Events |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Severe | 0 Events |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Moderate | 4 Events |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Mild | 23 Events |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Severe | 0 Events |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Moderate | 3 Events |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Mild | 37 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in Subjects who received Dose 3 : Moderate | 5 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Moderate | 5 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in Subjects who received Dose 3 : Severe | 0 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Moderate | 3 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Severe | 0 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in Subjects who received Dose 3 : Mild | 17 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Mild | 28 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Severe | 0 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Mild | 23 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in Subjects who received Dose 3 : Mild | 17 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Severe | 0 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Mild | 33 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Moderate | 3 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Mild | 35 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Moderate | 10 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Severe | 0 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in Subjects who received Dose 3 : Moderate | 3 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in Subjects who received Dose 3 : Severe | 0 Events |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Moderate | 0 Events |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Severe | 0 Events |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Moderate | 1 Events |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Severe | 0 Events |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Mild | 18 Events |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Mild | 16 Events |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Severe | 0 Events |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Mild | 17 Events |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Moderate | 0 Events |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Moderate | 0 Events |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Mild | 21 Events |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Severe | 0 Events |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Moderate | 4 Events |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Mild | 16 Events |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Severe | 0 Events |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Severe | 0 Events |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Moderate | 1 Events |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Mild | 22 Events |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Mild | 27 Events |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Moderate | 2 Events |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Moderate | 2 Events |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Mild | 18 Events |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Severe | 0 Events |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Severe | 0 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Mild | 16 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Mild | 25 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in Subjects who received Dose 3 : Severe | 0 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in Subjects who received Dose 3 : Moderate | 1 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Severe | 0 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Moderate | 2 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Moderate | 2 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Severe | 0 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in Subjects who received Dose 3 : Mild | 10 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in Subjects who received Dose 3 : Severe | 0 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Moderate | 3 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Mild | 22 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Severe | 0 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 2 : Mild | 15 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in Subjects who received Dose 3 : Mild | 6 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Moderate | 1 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in Subjects who received Dose 3 : Moderate | 0 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received Dose 1 : Severe | 0 Events |
Primary
Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series
Safety of 2-dose and 3-dose H5 influenza vaccination series as determined by occurrence of mild, moderate, or severe solicited systemic reactogenicity symptoms Subjects in A-D and G-J did not receive 3 doses
Time frame: 8 days post-vaccination
Population: If a subject experienced multiple occurrences of the same solicited local AE, only the most severe solicited local AE was counted.~Number Analyzed per Row = Participants with available data Subjects in A-D and G-J did not receive 3 doses
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Severe | 0 Events |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Moderate | 19 Events |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Mild | 39 Events |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Moderate | 6 Events |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Severe | 0 Events |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Mild | 45 Events |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Severe | 0 Events |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Moderate | 12 Events |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Moderate | 10 Events |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Mild | 33 Events |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Mild | 41 Events |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Severe | 0 Events |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Mild | 22 Events |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Severe | 0 Events |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Severe | 6 Events |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Moderate | 8 Events |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Moderate | 7 Events |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Mild | 32 Events |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Moderate | 19 Events |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Mild | 46 Events |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Severe | 0 Events |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Mild | 43 Events |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Moderate | 20 Events |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Severe | 0 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Severe | 0 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Mild | 23 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 3 : Severe | 1 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 3 : Moderate | 19 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Moderate | 6 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 3 : Mild | 19 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Severe | 0 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Moderate | 8 Events |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Mild | 17 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Moderate | 21 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Mild | 40 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Moderate | 19 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 3 : Mild | 32 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 3 : Moderate | 12 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 3 : Severe | 1 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Mild | 37 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Severe | 0 Events |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Severe | 0 Events |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Mild | 16 Events |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Mild | 29 Events |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Moderate | 13 Events |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Severe | 0 Events |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Moderate | 4 Events |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Severe | 0 Events |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Moderate | 0 Events |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Mild | 28 Events |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Mild | 6 Events |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Severe | 0 Events |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Severe | 0 Events |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Moderate | 2 Events |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Severe | 0 Events |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Severe | 0 Events |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Mild | 24 Events |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Moderate | 6 Events |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Moderate | 3 Events |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Mild | 29 Events |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Moderate | 6 Events |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Mild | 4 Events |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Moderate | 6 Events |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Severe | 0 Events |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Severe | 0 Events |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Mild | 21 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Severe | 0 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 3 : Severe | 0 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 3 : Mild | 11 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Moderate | 6 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Mild | 32 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Mild | 17 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 3 : Moderate | 2 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Severe | 0 Events |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Moderate | 5 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Mild | 11 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Severe | 0 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Moderate | 2 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Moderate | 19 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 3 : Severe | 0 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 2 : Severe | 0 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 1 : Mild | 23 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 3 : Mild | 9 Events |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series | AEs in subjects who received dose 3 : Moderate | 0 Events |
Primary
Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series
Serum hemagglutination inhibition (HAI) antibody seroprotection rate (SPR)
Time frame: Day 43
Population: Seroprotection Rate by Strain (with 95% confidence interval) of HAI antibodies at Day 43 (21 days after Dose 2)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 47.2 percentage of participants |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 28.3 percentage of participants |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 26.4 percentage of participants |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 75.5 percentage of participants |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 13.2 percentage of participants |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 40.4 percentage of participants |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 19.2 percentage of participants |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 38.5 percentage of participants |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 55.8 percentage of participants |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 25.0 percentage of participants |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 31.5 percentage of participants |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 11.1 percentage of participants |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 44.4 percentage of participants |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 20.4 percentage of participants |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 38.9 percentage of participants |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 46.2 percentage of participants |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 50.0 percentage of participants |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 34.6 percentage of participants |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 65.4 percentage of participants |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 32.7 percentage of participants |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 67.5 percentage of participants |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 12.5 percentage of participants |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 22.5 percentage of participants |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 37.5 percentage of participants |
| e dk/BANG With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 32.5 percentage of participants |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 80.0 percentage of participants |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 2.2 percentage of participants |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 17.8 percentage of participants |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 15.6 percentage of participants |
| f gf/WA With AS03 Adjuvant, Then Bhg/QL With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 4.4 percentage of participants |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 3.9 percentage of participants |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 15.7 percentage of participants |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 0.0 percentage of participants |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 39.2 percentage of participants |
| g VN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 13.7 percentage of participants |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 9.6 percentage of participants |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 17.3 percentage of participants |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 15.4 percentage of participants |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 23.1 percentage of participants |
| h IN With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 13.5 percentage of participants |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 33.3 percentage of participants |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 33.3 percentage of participants |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 9.8 percentage of participants |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 3.9 percentage of participants |
| i dk/BANG With MF59 Adjuvant, Then gf/WA With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 37.3 percentage of participants |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 37.3 percentage of participants |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 3.9 percentage of participants |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 13.7 percentage of participants |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 13.7 percentage of participants |
| j gf/WA With MF59 Adjuvant, Then IN With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 11.8 percentage of participants |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 6.5 percentage of participants |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 10.9 percentage of participants |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 6.5 percentage of participants |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 50.0 percentage of participants |
| k dk/BANG With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 26.1 percentage of participants |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 18.4 percentage of participants |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 5.3 percentage of participants |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 13.2 percentage of participants |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 63.2 percentage of participants |
| l gf/WA With MF59 Adjuvant, Then Bhg/QL With MF59 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 2-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 2.6 percentage of participants |
Primary
Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series
Serum hemagglutination inhibition (HAI) antibody seroprotection rate (SPR)
Time frame: Day 163
Population: Seroprotection Rate by Strain (with 95% confidence interval) of HAI antibodies at Day 163 (21 days after Dose 3). Measurement of participants remaining rather than enrolled.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 90.0 percentage of participants |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 75.0 percentage of participants |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 72.5 percentage of participants |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 90.0 percentage of participants |
| a VN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 60.0 percentage of participants |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 62.2 percentage of participants |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 80.0 percentage of participants |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 73.3 percentage of participants |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 57.8 percentage of participants |
| b IN With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 82.2 percentage of participants |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 63.0 percentage of participants |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 28.3 percentage of participants |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 50.0 percentage of participants |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 63.0 percentage of participants |
| c dk/BANG With AS03 Adjuvant, Then gf/WA With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 45.7 percentage of participants |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/Vietnam/1203/2004 (H5N1) (VN) | 60.5 percentage of participants |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/Indonesia/05/2005 (H5N1) (IN) | 15.8 percentage of participants |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/gyrfalcon/Washington/41088-6/2014 (H5N8) (gf/WA) | 52.6 percentage of participants |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/duck/Bangladesh/19097/2013 (H5N1) (dk/BANG) | 26.3 percentage of participants |
| d gf/WA With AS03 Adjuvant, Then IN With AS03 Adjuvant | Percentage of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Seroprotection Against Vaccine Strains Following 3-dose H5 Influenza Vaccination Series | A/barheaded goose/QinghaiLake/1A/2005(H5N1)bhg/QL | 39.5 percentage of participants |